Literature DB >> 30898703

Transfection with p21 and p53 tumor suppressor plasmids suppressed breast tumor growth in syngeneic mouse model.

Nabilah Ibnat1, Nur Izyani Kamaruzman1, Maeirah Ashaie1, Ezharul Hoque Chowdhury2.   

Abstract

Treatment of breast cancer by delivering important tumor suppressor plasmids is a promising approach in the field of clinical medicine. We transfected p21 and p53 tumor suppressor plasmids, into different breast cancer cell lines using inorganic nanoparticles (NPs) of carbonate apatite to evaluate the effect of gene expression on reducing breast cancer cell growth. In triple negative MDA-MB-231 breast cancer cell line, the cytotoxicity assay upon combined delivery of p21 and p53 plasmid loaded NPs showed significant decrease in cell growth compared to distinct p21 or p53 treatments. Also, in MCF-7 and 4T1 cell lines, significant reduction in cellular growth was observed following p21 or p53 plasmid transfection. The Western blot data showed that NP loaded p21 and p53 transgene delivery in MDA-MB-231 cell line resulted in a noteworthy decrease in phosphorylated form of MAPK protein of MAPK/ERK pathway. The in vivo studies in syngeneic breast cancer mouse model demonstrated that the rate of growth and final tumor volume were reduced to a greater extent in mice that received intravenous injection of p21 + NP and p53 + NP therapeutics.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Carbonate apatite nanoparticle; Gene therapy; Transgene; Tumor regression; Tumor suppressor

Mesh:

Substances:

Year:  2019        PMID: 30898703     DOI: 10.1016/j.gene.2019.02.082

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  7 in total

1.  RDM1 promotes critical processes in breast cancer tumorigenesis.

Authors:  Yajun Chen; Zhengwang Sun; Tianying Zhong
Journal:  J Cell Mol Med       Date:  2019-06-20       Impact factor: 5.310

Review 2.  p21 in Cancer Research.

Authors:  Bahar Shamloo; Sinem Usluer
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

3.  Ginsenoside Rg1 improves pathological damages by activating the p21‑p53‑STK pathway in ovary and Bax‑Bcl2 in the uterus in premature ovarian insufficiency mouse models.

Authors:  Lianli He; Xiaojuan Wang; Daigang Cheng; Zhengai Xiong; Xiaoyun Liu
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

4.  The role of splicing factor PRPF8 in breast cancer.

Authors:  Difei Cao; Jiaying Xue; Guoqing Huang; Jing An; Weiwei An
Journal:  Technol Health Care       Date:  2022       Impact factor: 1.205

5.  Carbonate Apatite and Hydroxyapatite Formulated with Minimal Ingredients to Deliver SiRNA into Breast Cancer Cells In Vitro and In Vivo.

Authors:  Rowshan Ara Islam; Hamed Al-Busaidi; Rahela Zaman; Syafiq Asnawi Zainal Abidin; Iekhsan Othman; Ezharul Hoque Chowdhury
Journal:  J Funct Biomater       Date:  2020-09-10

6.  Characterization and Evaluation of Bone-Derived Nanoparticles as a Novel pH-Responsive Carrier for Delivery of Doxorubicin into Breast Cancer Cells.

Authors:  Sheikh Tanzina Haque; Rowshan Ara Islam; Siew Hua Gan; Ezharul Hoque Chowdhury
Journal:  Int J Mol Sci       Date:  2020-09-14       Impact factor: 5.923

7.  Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1.

Authors:  Martin Götte; Burkhard Greve; Fabian M Troschel; Heike Palenta; Katrin Borrmann; Kristin Heshe; San Hue Hua; George W Yip; Ludwig Kiesel; Hans Theodor Eich
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-22       Impact factor: 4.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.